Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) Invested Capital (2019 - 2025)

Pulmonx (LUNG) has disclosed Invested Capital for 7 consecutive years, with $37.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 71.69% to $37.1 million in Q3 2025 year-over-year; TTM through Jun 2025 was $106.2 million, a 23.26% decrease, with the full-year FY2024 number at $122.7 million, down 20.92% from a year prior.
  • Invested Capital was $37.1 million for Q3 2025 at Pulmonx, down from $106.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $233.5 million in Q1 2021 to a low of $37.1 million in Q3 2025.
  • A 5-year average of $156.5 million and a median of $170.9 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 11765.19% in 2021, then plummeted 79.41% in 2023.
  • Pulmonx's Invested Capital stood at $210.1 million in 2021, then dropped by 18.67% to $170.9 million in 2022, then decreased by 9.2% to $155.2 million in 2023, then dropped by 20.92% to $122.7 million in 2024, then tumbled by 69.74% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Invested Capital are $37.1 million (Q3 2025), $106.2 million (Q2 2025), and $114.9 million (Q1 2025).